scholarly article | Q13442814 |
P50 | author | Henrik Enghusen Poulsen | Q33310622 |
Filip K Knop | Q59659637 | ||
Tina Vilsbøll | Q60393741 | ||
P2093 | author name string | Jørgen Rungby | |
Emil List Larsen | |||
Vanja Cejvanovic | |||
Laura Kofoed Kjær | |||
P2860 | cites work | SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? | Q26750510 |
Clinical Relevance of Biomarkers of Oxidative Stress | Q26785512 | ||
Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring | Q26861082 | ||
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials | Q28710019 | ||
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q34457919 | ||
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity | Q34524690 | ||
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Q34670462 | ||
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
Intensive glucose control and macrovascular outcomes in type 2 diabetes. | Q34995674 | ||
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people | Q35004093 | ||
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy | Q35043750 | ||
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study | Q35117192 | ||
Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients | Q35563607 | ||
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | Q35903101 | ||
Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: a population-based cohort study. | Q36629664 | ||
Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. | Q36750672 | ||
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study | Q36820604 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker in type 2 diabetes | Q37912415 | ||
RNA modifications by oxidation: a novel disease mechanism? | Q37981450 | ||
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | Q37981884 | ||
Assays for urinary biomarkers of oxidatively damaged nucleic acids | Q37986872 | ||
SPIRIT 2013 statement: defining standard protocol items for clinical trials | Q38072250 | ||
Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid | Q38116269 | ||
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension | Q38710995 | ||
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index | Q41104925 | ||
Simvastatin and oxidative stress in humans: A randomized, double-blinded, placebo-controlled clinical trial | Q42725614 | ||
Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study | Q43181601 | ||
Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis | Q43290649 | ||
Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry | Q43714076 | ||
Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials | Q46420088 | ||
Oltipraz chemoprevention trial in Qidong, People's Republic of China: Unaltered oxidative biomarkers | Q61794754 | ||
P433 | issue | 5 | |
P921 | main subject | placebo | Q269829 |
type 2 diabetes | Q3025883 | ||
empagliflozin | Q5373824 | ||
P304 | page(s) | e014728 | |
P577 | publication date | 2017-05-09 | |
P1433 | published in | BMJ Open | Q17003470 |
P1476 | title | The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial | |
P478 | volume | 7 |